Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1988 Apr;81(4):1103–1110. doi: 10.1172/JCI113423

Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition.

W S Colucci 1, A R Denniss 1, G F Leatherman 1, R J Quigg 1, P L Ludmer 1, J D Marsh 1, D F Gauthier 1
PMCID: PMC329637  PMID: 2832444

Abstract

We infused dobutamine into the left main coronary artery of 24 patients with severe congestive heart failure (CHF) and 8 normal subjects without hemodynamic dysfunction. The maximal +dP/dt response to intracoronary (IC) dobutamine in CHF patients was only 37% of that in normals. This decrease in maximal response was not associated with a rightshift in the EC50 for dobutamine's effect on +dP/dt, or a decrease in the affinity of myocardial beta adrenergic receptors for dobutamine determined in vitro. In nine of the CHF patients, IC dobutamine infusion was followed by IC infusion of the phosphodiesterase inhibitor milrinone, and subsequently, by a second IC infusion of dobutamine. After IC milrinone, the increase in +dP/dt caused by IC dobutamine (74 +/- 10%) was significantly greater than that caused by the first infusion of dobutamine (52 +/- 11%; P less than 0.003) or milrinone (42 +/- 6%; P less than 0.001). Resting plasma norepinephrine was markedly elevated in CHF patients (837 +/- 208 ng/liter), but not in normal subjects (142 +/- 32 ng/liter); and the increase in +dP/dt caused by IC dobutamine was inversely related to resting plasma norepinephrine levels (r = -0.653; P less than 0.001). IC dobutamine caused a dose-related decrease in plasma norepinephrine (maximal effect, -160 +/- 31 ng/liter; P less than 0.001). Thus, (a) the maximal inotropic response to dobutamine is markedly depressed in patients with severe CHF, and is significantly greater after pretreatment with the phosphodiesterase inhibitor milrinone; (b) the impairment in inotropic response to dobutamine is inversely related to circulating norepinephrine levels; and (c) myocardial stimulation by dobutamine results in withdrawal of sympathetic tone.

Full text

PDF
1103

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alousi A. A., Stankus G. P., Stuart J. C., Walton L. H. Characterization of the cardiotonic effects of milrinone, a new and potent cardiac bipyridine, on isolated tissues from several animal species. J Cardiovasc Pharmacol. 1983 Sep-Oct;5(5):804–811. doi: 10.1097/00005344-198309000-00015. [DOI] [PubMed] [Google Scholar]
  2. Axelrod R. J., De Marco T., Dae M., Botvinick E. H., Chatterjee K. Hemodynamic and clinical evaluation of piroximone, a new inotrope-vasodilator agent, in severe congestive heart failure. J Am Coll Cardiol. 1987 May;9(5):1124–1130. doi: 10.1016/s0735-1097(87)80317-0. [DOI] [PubMed] [Google Scholar]
  3. Bristow M. R., Ginsburg R., Minobe W., Cubicciotti R. S., Sageman W. S., Lurie K., Billingham M. E., Harrison D. C., Stinson E. B. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982 Jul 22;307(4):205–211. doi: 10.1056/NEJM198207223070401. [DOI] [PubMed] [Google Scholar]
  4. Bristow M. R., Ginsburg R., Strosberg A., Montgomery W., Minobe W. Pharmacology and inotropic potential of forskolin in the human heart. J Clin Invest. 1984 Jul;74(1):212–223. doi: 10.1172/JCI111404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bristow M. R., Ginsburg R., Umans V., Fowler M., Minobe W., Rasmussen R., Zera P., Menlove R., Shah P., Jamieson S. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986 Sep;59(3):297–309. doi: 10.1161/01.res.59.3.297. [DOI] [PubMed] [Google Scholar]
  6. Bristow M. R., Kantrowitz N. E., Ginsburg R., Fowler M. B. Beta-adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol. 1985 Jul;17 (Suppl 2):41–52. doi: 10.1016/0022-2828(85)90007-0. [DOI] [PubMed] [Google Scholar]
  7. Feldman M. D., Copelas L., Gwathmey J. K., Phillips P., Warren S. E., Schoen F. J., Grossman W., Morgan J. P. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation. 1987 Feb;75(2):331–339. doi: 10.1161/01.cir.75.2.331. [DOI] [PubMed] [Google Scholar]
  8. Firth B. G., Ratner A. V., Grassman E. D., Winniford M. D., Nicod P., Hillis L. D. Assessment of the inotropic and vasodilator effects of amrinone versus isoproterenol. Am J Cardiol. 1984 Dec 1;54(10):1331–1336. doi: 10.1016/s0002-9149(84)80092-2. [DOI] [PubMed] [Google Scholar]
  9. Fowler M. B., Laser J. A., Hopkins G. L., Minobe W., Bristow M. R. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation. 1986 Dec;74(6):1290–1302. doi: 10.1161/01.cir.74.6.1290. [DOI] [PubMed] [Google Scholar]
  10. Gage J., Rutman H., Lucido D., LeJemtel T. H. Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation. 1986 Aug;74(2):367–373. doi: 10.1161/01.cir.74.2.367. [DOI] [PubMed] [Google Scholar]
  11. Ganz W., Tamura K., Marcus H. S., Donoso R., Yoshida S., Swan H. J. Measurement of coronary sinus blood flow by continuous thermodilution in man. Circulation. 1971 Aug;44(2):181–195. doi: 10.1161/01.cir.44.2.181. [DOI] [PubMed] [Google Scholar]
  12. Harden T. K. Agonist-induced desensitization of the beta-adrenergic receptor-linked adenylate cyclase. Pharmacol Rev. 1983 Mar;35(1):5–32. [PubMed] [Google Scholar]
  13. Hayes J. S., Bowling N., Pollock G. D. Effects of beta adrenoceptor down-regulation on the cardiovascular responses to the stereoisomers of dobutamine. J Pharmacol Exp Ther. 1985 Oct;235(1):58–65. [PubMed] [Google Scholar]
  14. Jaski B. E., Fifer M. A., Wright R. F., Braunwald E., Colucci W. S. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest. 1985 Feb;75(2):643–649. doi: 10.1172/JCI111742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Katz A. M. Cyclic adenosine monophosphate effects on the myocardium: a man who blows hot and cold with one breath. J Am Coll Cardiol. 1983 Jul;2(1):143–149. doi: 10.1016/s0735-1097(83)80387-8. [DOI] [PubMed] [Google Scholar]
  16. Leier C. V., Unverferth D. V. Drugs five years later. Dobutamine. Ann Intern Med. 1983 Oct;99(4):490–496. doi: 10.7326/0003-4819-99-4-490. [DOI] [PubMed] [Google Scholar]
  17. Leier C. V., Unverferth D. V., Kates R. E. The relationship between plasma dobutamine concentrations and cardiovascular responses in cardiac failure. Am J Med. 1979 Feb;66(2):238–242. doi: 10.1016/0002-9343(79)90537-0. [DOI] [PubMed] [Google Scholar]
  18. Ludmer P. L., Wright R. F., Arnold J. M., Ganz P., Braunwald E., Colucci W. S. Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique. Circulation. 1986 Jan;73(1):130–137. doi: 10.1161/01.cir.73.1.130. [DOI] [PubMed] [Google Scholar]
  19. Marsh J. D., Smith T. W. Receptors for beta-adrenergic agonists in cultured chick ventricular cells. Relationship between agonist binding and physiologic effect. Mol Pharmacol. 1985 Jan;27(1):10–18. [PubMed] [Google Scholar]
  20. Monrad E. S., McKay R. G., Baim D. S., Colucci W. S., Fifer M. A., Heller G. V., Royal H. D., Grossman W. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. Circulation. 1984 Dec;70(6):1030–1037. doi: 10.1161/01.cir.70.6.1030. [DOI] [PubMed] [Google Scholar]
  21. Munson P. J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  22. Newman W. H., Webb J. G. A differential inotropic responsiveness to isoprenaline and ouabain in dogs with heart failure. Cardiovasc Res. 1980 Sep;14(9):530–536. doi: 10.1093/cvr/14.9.530. [DOI] [PubMed] [Google Scholar]
  23. Peuler J. D., Johnson G. A. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. Life Sci. 1977 Sep 1;21(5):625–636. doi: 10.1016/0024-3205(77)90070-4. [DOI] [PubMed] [Google Scholar]
  24. RALL T. W., WEST T. C. The potentiation of cardiac inotropic responses to norepinephrine by theophylline. J Pharmacol Exp Ther. 1963 Mar;139:269–274. [PubMed] [Google Scholar]
  25. Ruffolo R. R., Jr, Spradlin T. A., Pollock G. D., Waddell J. E., Murphy P. J. Alpha and beta adrenergic effects of the stereoisomers of dobutamine. J Pharmacol Exp Ther. 1981 Nov;219(2):447–452. [PubMed] [Google Scholar]
  26. Stiles G. L., Caron M. G., Lefkowitz R. J. Beta-adrenergic receptors: biochemical mechanisms of physiological regulation. Physiol Rev. 1984 Apr;64(2):661–743. doi: 10.1152/physrev.1984.64.2.661. [DOI] [PubMed] [Google Scholar]
  27. Vatner D. E., Vatner S. F., Fujii A. M., Homcy C. J. Loss of high affinity cardiac beta adrenergic receptors in dogs with heart failure. J Clin Invest. 1985 Dec;76(6):2259–2264. doi: 10.1172/JCI112235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Wagner J., Schümann H. J., Knorr A., Rohm N., Reidemeister J. C. Stimulation by adrenaline and dopamine but not by noradrenaline of myocardial alpha-adrenoceptors mediating positive inotropic effects in human atrial preparations. Naunyn Schmiedebergs Arch Pharmacol. 1980 May;312(1):99–102. doi: 10.1007/BF00502581. [DOI] [PubMed] [Google Scholar]
  29. Wallenstein S., Zucker C. L., Fleiss J. L. Some statistical methods useful in circulation research. Circ Res. 1980 Jul;47(1):1–9. doi: 10.1161/01.res.47.1.1. [DOI] [PubMed] [Google Scholar]
  30. Williams R. S., Bishop T. Selectivity of dobutamine for adrenergic receptor subtypes: in vitro analysis by radioligand binding. J Clin Invest. 1981 Jun;67(6):1703–1711. doi: 10.1172/JCI110208. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES